Preventing congestive heart failure

American Family Physician

Volumn 57, Issue 8, 1998, Pages 1901-1904

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE;

BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPERTENSION; REVIEW; VALVULAR HEART DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHIES; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HEART VALVE DISEASES; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0032522569     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Effects of treatment on morbidity in hypertension. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 1972;45:991-1004.
2. Forrester JS, Merz CN, Bush TL, Cohn JN, Hunninghake DB, Parthasarathy S. et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol 1996;27:991-1006.
3. Steering Committee of the Physicians' Health Study Research Group: final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
4. Francis GS, Johnson TH, Ziesche S, Berg M, Boosalis P, Cohn JN. Marked spontaneous improvement in ejection fraction in patients with congestive heart failure. Am J Med 1990;89:303-7.
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-91 [Published erratum appears in N Engl J Med 1992;327:1768].
6. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972;287:781-7.
7. Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation 1990; 81(Suppl 2):48-53.
8. Kostis JB, Davis BR, Cutler J, Grimm RH Jr., Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278:212-6.
9. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
10. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:1161-72.
11. McDonald KM, Carlyle PR Matthews J, Hauer K, Elbers T, Hunter D, et al. Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Physicians 1990;103:229-35.
12. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8.
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
14. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
15. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-5.
16. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92:3132-7.
17. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
18. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage and infarct location. Circulation 1988;78:906-19 [Published erratum appears in Circulation 1989;79:1151].
19. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1994; 343:1115-22.